The role of glutamate in the pathophysiology of Parkinson's disease

Functional Neurology

Volumn 11, Issue 1, 1996, Pages 3-15

  Blandini, Fabio ^a,c   Greenamyre, J Timothy ^b   Nappi, Giuseppe ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

basal ganglia; excitotoxicity; glutamate; mitochondria; Parkinson's disease

Indexed keywords

7 CHLOROKYNURENIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMANTADINE; BUDIPINE; DECAHYDRO 6 PHOSPHONOMETHYL 3 ISOQUINOLINECARBOXYLIC ACID; DIZOCILPINE; EXCITATORY AMINO ACID RECEPTOR; EXCITOTOXIN; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; LEVODOPA; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROTOXIN; REMACEMIDE;

BASAL GANGLION; BRAIN PROTECTION; NEUROTRANSMISSION; PARKINSON DISEASE; PATHOPHYSIOLOGY; REVIEW;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; BASAL GANGLIA; DISEASE MODELS, ANIMAL; DOPAMINE; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HUMANS; ION CHANNEL GATING; MITOCHONDRIA; NEURAL PATHWAYS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PRIMATES; RATS; RECEPTORS, AMPA; RECEPTORS, GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0029993255     PISSN: 03935264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Ehringer H, Hornykiewicz O. Verteilung von noradrenalin und dopamin (3-hydroxytyramin) im gehirn des menschen und ihr verhalten bei erkrankungen des extrapyramidalen systems. Klinische Wochenschrift 1960:1236-1239
2. Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993;361:31-39
3. Collingridge GL, Singer W. Excitatory amino acid receptors and synaptic plasticity. Trends Pharmacol Sci 1990;11:290-296
4. Pin JP, Duvoisin R. Review: neurotransmitter receptors I. The metabotropic glutamate receptors: structure and functions. Neuropharmacology 1995;34:1-26
5. Greenamyre JT. Porter RHP. Anatomy and physiology of glutamate in the CNS. Neurology 1994;44(suppl. 8): S7-S13
6. McBain CJ, Mayer L. N-methyl-D-aspartic acid receptor structure and function. Physiol Rev 1994;74:723-760
7. Bettler B, Mulle C. Review: neurotransmitter receptors II. AMPA and kainate receptors. Neuropharmacology 1995;34:123-139
8. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989;12:366-375
9. Gerfen CR. The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci 1992;15:133-139
10. Graybiel AM. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 1990;13:244-254
11. Parent A, Hazrati LN. Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res Rev 1995;20:128-154
12. Kaatz KW, Albin RL. Intrastriatal and intrasubthalamic stimulation of metabotropic glutamate receptors: a behavioral and fos immunoistochemical study. Neuroscience 1995;66:55-65
13. Aides LD. Thalamic connectivity of rat somatic motor cortex. Brain Res Bull 1988; 20:333-348
14. Tallaksen-Greene SJ, Wiley RG, Albin RL. Localization of striatal excitatory amino acid binding site subtypes to striatonigral projection neurons. Brain Res 1992;594:165-170
15. Landwehrmeyer GB, Standaert DG, Testa CM, Penney JB, Young AB. NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. J Neurosci 1995;15:5297-5307
16. Tailaksen-Greene SJ, Albin RL. Localization of AMPA-selective excitatory amino acid receptor subunits in identified populations of striatal neurons. Neuroscience 1994;61:509-519
17. Calabresi P, Mercuri NB, Sancessario G, Bernardi G. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain 1993; 116:433-452
18. Anderson JJ, Kuo S, Chase TN. Endogenous excitatory amino acids tonically stimulate striatal acetylcholine release through NMDA but not AMPA receptors. Neurosci Lett 1994;176:264-268
19. Albin RL, Makowiec RL, Hollingsworth Z, Dure LS, Penney JB, Young AB. Excitatory amino acid binding sites in the basal ganglia of the rat: a quantitative autoradiographic study. Neuroscience 1992;46:35-48
20. Soltis RP, Anderson LA, Walters JR, Kelland MD. A role for non-NMDA excitatory amino acid receptors in regulating the basal activity of rat globus pallidus neurons and their activation by the subthalamic nucleus. Brain Res 1994;666:21-30
21. Hamada I, DeLong MR. Effects of subthalamic nucleus lesions on pallidal discharge in the primate. Biomedical Research 1993; 14(suppl. 1):43-45
22. Tzagournissakis M, Dermon CR, Savaki HE. Functional metabolic mapping of the rat brain during unilateral electrical stimulation of the subthalamic nucleus. J Cereb Blood Flow Metab 1994;14:132-144
23. Blandini F, Greenamyre JT. Effect of subthalamic nucleus lesion on mitochondrial enzyme activity in rat basal ganglia. Brain Res 1995;669:59-66
24. Blandini F, Porter RHP, Greenamyre JT. Autoradiographic study of mitochondrial complex I and glutamate receptors in the basal ganglia of rats after unilateral subthalamic lesion. Neurosci Lett 1995;186:99-102
25. Robledo P, Feger J. Excitatory influence of rat subthalamic nucleus to substantia nigra pars reticulata and the pallidal complex: electrophysiological data. Brain Res 1990;518:47-54
26. 14C]GABA uptake in the basal ganglia of rats following lesions in the subthalamic region suggest a role for excitatory amino acid but not GABA-mediated transmission in subthalamic nucleus efferents. Exp Neurol 1991;113:171-181
27. Olney JW, Ho OL, Rhee V. Cytotoxic effects of acidic amino acids on the infant mouse central nervous sytem. Exp Brain Res 1971;14:61-76
28. Meldrum B, Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 1990; 11:379-387
29. Rothman SM. Excitotoxins: Possible mechanisms of action. Ann NY Acad Sci 1992; 648:132-139
30. Rothman SM, Olney JW. Excitotoxicity and the NMDA receptor. Trends Neurosci 1987;10:299-301
31. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993;262:689-695
32. Orrenius S, Nicotera P. The calcium ion and cell death. J Neural Transm(suppl.) 1994;43:S1-S11
33. Kure S, Tominaga T, Yoshimoto T, Tada K, Narisawa K. Glutamate triggers internucleosomal DNA cleavage in neuronal cells. Biochem Biophys Res Commun 1991;179:39-45
34. Peng T-I, Sheu S-S, Greenamyre JT. Visualization of NMDA-induced mitochondrial calcium uptake in striatal neurons using confocal microscopy. Society for Neuroscience Abstracts 1995;21:1343
35. Reynolds IJ, Hastings TG. Glutamate induces the production of reactive oxygen species in cultured forebrain neurons following NMDA receptor activation. J Neurosci 1995;15:3318-3327
36. Greenamyre JT, Young AB, Penney JB. NMDA receptor abnormalities in neurodegenerative disorders. In: Krogsgaard-Larsen P, Christensen SB, Kofod H eds New Leads and Targets in Drug Research. Munksgaard Copenhagen: Alfred Benzon Symposium 1992;vol.33:304-314
37. Beneviste H, Drejer J, Schousboe A, Diemer NH. Elevation of extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem 1982;43:1369-1374
38. Rothman SM, Olney JW. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol 1986;19:105-111
39. 3H]glutamate uptake into synaptosomes. J Neurochem 1986;47:1614-1619
40. Kanai Y, Smith CP, Hediger MA. The elusive transporter with a high affinity for glutamate. Trends Neurosci 1993;16:365-370
41. Glynn IA, Karlish SJD. The sodium pump. Annu Rev Physiol 1975;37:13-55
42. +, and adenosine triphosphate in isolated brain synaptosomes. J Gen Physiol 1990;95:591-616
43. Novelli A, Reilly JA, Lysko PG, Henneberry RC. Glutamate becomes neurotoxic via the NMDA receptor when intracellular energy levels are reduced. Brain Res 1988; 451:205-212
44. Albin RL, Greenamyre JT. Alternative excitotoxic hypotheses. Neurology 1992;42: 733-738
45. Beal MF, Hyman BT, Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci 1993;16:125-131
46. Beal MF, Swartz KJ, Hyman BT, Storey E, Finn SF, Koroshetz W. Aminoxyacetic acid results in excitotoxin lesions by a novel indirect mechanism. J Neurochem 1991;57: 1068-1073
47. Beal MF, Brouillet E, Jenkins BG et al. Neurochemical and histologic characterization of striatal excitotoxic lesion produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 1993;13:4181-4192
48. Greene JG, Porter RHP, Eller RV, Greenamyre JT. Inhibition of succinate dehydrogenase by malonic acid produces an "excitotoxic" lesion in rat striatum. J Neurochem 1993;61:1151-1154
49. Greene JG, Greenamyre JT. Characterization of the excitotoxic potential of the reversible succinate dehydrogenase inhibitor malonate. J Neurochem 1995;64:430-436
50. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990;13:281-285
51. Markey SP, Johannessen JN, Chiueh CC, Burns RS, Herkenham MA. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 1984;311:464-467
52. Chiba K, Trevor AJ, Castagnoli N Jr. Metabolism of the neurotoxic tertiary amine. MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 1984;120:574-578
53. Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyride, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropiridine. Life Sci 1985;36:2503-2508
54. Ramsay RR, Singer TP. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropiridine (MPTP). J Biol Chem 1986;261:7585-7587
55. Cesura AM, Ritter A, Picotti GB, Da Prada M. Uptake, release, and subcellular localization of 1-methyl-4-phenylpiridinium in blood platelets. J Neurochem 1987;49:138-145
56. Buckman TD, Chang R, Sutphin MS, Eiduson S. Interaction of 1-methyl-4-phenylpiridinium ion with human platelets. Biochem Biophys Res Commun 1988;151:897-904
57. 3H]dihydrorotenone binding to complex I in intact human platelets. Anal Biochem 1995;230:16-19
58. Greenamyre JT, Higgins DS, Eller RV. Quantitative autoradiography of dihydrorotenone binding to complex I of the electron transport chain. J Neurochem 1992; 59:747-749
59. + neurotoxicity by N-methyl-D-aspartate antagonists. Nature 1991;349: 414-418
60. Storey E, Hyman BT, Jenkins B et al. 1-Methyl-4-phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism. J Neurochem 1992;58:1975-1978
61. Marey-Semper I, Gelman M, Lévi-Strauss M. A selective toxicity toward cultured mesencephalic dopaminergic neurons is induced by the synergistic effects of energetic metabolism impairment and NMDA receptor activation. J Neurosci 1995;15:5912-5918
62. Mizuno Y, Suzuki K, Ohta S. Postmortem changes in mitochondrial respiratory enzymes in brain and a preliminary observation in Parkinson's disease. J Neurol Sci 1990;96:49-57
63. Schapira AHV, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990;54:823-827
64. Janetzky B, Hauck S, Youdim MBH et al. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci Lett 1994;169:126-128
65. Parker WD, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 1989;26:719-723
66. Krige D, Carroll MT, Cooper JM, Marsden CD, Schapira AHV. Platelet mitochondrial function in Parkinson's disease. Ann Neurol 1992;32:782-788
67. Yoshino H, Nakagawa-Hattori Y, Kondo T, Mizuno Y. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease. J Neural Transm Park Dis Dement Sect 1992;4:27-34
68. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993;262:689-695
69. Jenner P. Oxidative damage in neurodegenerative disease. Lancet 1994;344:796-798
70. Sanchez-Ramos JR, Overvik E, Ames BN. A marker of oxyradical-mediated DNA damage (8-hydroxy-2'deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 1994;3:197-204
71. Allen KL, Almeida A, Bates TE, Clark JB. Changes of respiratory chain activity in mitochondrial and synaptosomal fractions isolated from the gerbil brain after graded ischaemia. J Neurochem 1995;64:2222-2229
72. Cleeter MW, Cooper JM, Schapira AH. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J Neurochem 1992;58:786-789
73. Perry TL, Young VW. Idiopathic Parkinson's disease, progressive sopranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci Lett 1986;67:269-274
74. Sofic E, Lange KW, Jellinger K, Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 1992;142:128-130
75. Sian J, Dexter DT, Lees AJ et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994;36:348-355
76. Mithöfer K, Sandy MS, Smith MT, DiMonte D. Mitochondrial poisons cause depletion of reduced glutathione in isolated hepatocytes. Arch Biochem Biophys 1992;295:132-136
77. Greenamyre JT Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease. J Neural Transm Gen Sect 1993;91:255-269
78. Yamamoto BK, Cooperman MA. Differential effects of chronic antipsychotic treatment on extracellular glutamate and dopamine concentrations. J Neurosci 1994;14:4159-4166
79. 2-mediated behavior in the 6-hydroxydopamine model of turning: relationship with c-fos expression. J Pharmacol Exp Ther 1992;260:402-408
80. Morelli M, Pinna A, Fenu S, Carta A, Cozzolino A, Di Chiara G. Diffferential effects of MK 801 and scopolamine on c-fos expression induced by L-dopa on the striatum of 6-hydroxydopamine lesioned rats. Synapse 1994;18:288-293
81. Porter RH, Greene JG, Higgins DS, Greenamyre JT. Polysynaptic regulation of glutamate receptors and mitochondrial enzyme activities in the basal ganglia of rats with unilateral dopamine depletion. J Neurosci 1994;14:7192-7199
82. Klockgether T, Turski L. Toward an understanding of the role of glutamate in experimental parkinsonism: agonist-sensitive sites in the basal ganglia. Ann Neurol 1993;34:585-593
83. Mitchell IJ, Clarke CE, Boyce S et al. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-1,2,3,6-tetrahydropyridine. Neuroscience 1989;32:226-231
84. Blandini F, Garcia-Osuna M, Greenamyre JT. Subthalamic ablation reverses changes in basal ganglia oxidative metabolism and motor response to apomorphine induced by nigrostriatal lesion. Society for Neuroscience Abstracts 1995;21:913
85. Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990;249:1436-1438
86. Limousin P, Pollak P, Benazzouz A et al. Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 1995;345:91-95
87. Brotchie JM, Mitchell IJ, Sambrook MA, Crossman AR. Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Mov Disord 1991;6:133-138
88. Klockgether T, Turski L, Honore T, et al. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann Neurol 1991;30:717-723
89. Klockgether T, Turski L. NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats. Ann Neurol 1990;28:536-539
90. Löschmann PA, Lange KA, Kunow M et al. Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-Dopa in models of Parkinson's disease. J Neural Transm Park Dis Dement Sect 1991;3:203-213
91. Greenamyre JT, Eller RV, Zhang Z, Ovadia A, Kurlan R, Gash DM. Antiparkinsonian effects of remacemide, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann Neurol 1994;35:655-661
92. Kornhuber J, Bormann J, Hubers M, Rusche K, Riederer P. Effects of the 1-aminoadamantines at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol 1991;206:297-300
93. Porter RHP, Greenamyre JT. Variations in the regional pharmacology of NMDA receptor channel blockers: Implications for therapeutic potential. J Neurochem 1995;64:614-623
94. 3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol 1989;166:589-590
95. Klockgether T, Jacobsen P, Löschmann PA, Turski L. The antiparkinsonian agent budipine is an N-methyl-D-aspartate antagonist. J Neural Transm Park Dis Dement Sect 1993;5:101-106